| Novel antiangiogenic peptide agents and their therapeutic and diagnostic use -> Monitor Keywords |
|
|
 
Novel antiangiogenic peptide agents and their therapeutic and diagnostic useRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) DoaiNovel antiangiogenic peptide agents and their therapeutic and diagnostic use description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20080096795, Novel antiangiogenic peptide agents and their therapeutic and diagnostic use. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application claims the benefit of the priority date of and is a continuation of U.S. application Ser. No. 09/076,675, filed May 12, 1998, which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application No. 60/046,394, filed May 13, 1997. BACKGROUND OF THE INVENTION [0002] A growing number of serious, debilitating and often fatal diseases are associated with angiogenesis. These diseases are cumulatively called angiogenic diseases. Under normal physiological conditions, angiogenesis in mammals is endogenously controlled throughout the lifetime and neovascularization rarely occurs except during embryonic development, the reproductive cycle, and wound healing. [0003] Examples of the pathological conditions leading to development of angiogenic diseases are, among others, arthritis, rheumatoid arthritis, atherosclerotic plaques, corneal graft neovascularization, wound healing, hypertrophic or keloid scars, proliferative retinopathy, diabetic retinopathy, macular degeneration, granulations, neovascular glaucoma and uveitis. [0004] Additionally, rapid and excessive angiogenesis accompanies the growth of the placenta and solid tumors. Many tumors seem to produce factors which increase cell division of vascular endothelial cells and stimulate the migration and organization of endothelial cells into vessels resulting in neovascularization. In addition, factors which inhibit angiogenesis may be turned off. Activation of angiogenesis, therefore, appears to be an essential stage in tumor progression. Various mammalian endogenous molecules have been identified as angiogenic factors stimulating angiogenesis directly or indirectly. These stimulators of angiogenesis include basic fibroblast growth factor (bFGF), vascular endothelial cell growth factor (VEGF), tumor necrosis factor-.alpha. (TNF-.alpha.), and angiogenin. [0005] The search for neovascularization inhibitors has been recently vigorously pursued. Currently, several antiangiogenic factors including thrombospondin, platelet factor-4, fumagillin, thalidomide angiostatin and endostatin are being studied. Several of these are in early clinical trials, e.g., fumagillin and thalidomide. [0006] Since there is no effective treatment available and since angiogenic diseases present a serous medical problem there is an ongoing need for new and more efficient antiangiogenic agents. [0007] Human hormones, such as growth hormone (hGH), prolactin (hPRL), placental lactogen (hPL) or growth hormone variant (hGH-V) are homologous protein hormones which are potent endogenous chemical substances asserting specific biological activities on their respective target organs. The biological activities of these hormones are not the same and they differ depending on the hormone and/or the hormone target organ. For example, growth hormone, which is a protein of the anterior lobe of the pituitary gland, promotes and regulates body growth and morphogenesis, fat mobilization and inhibitions of glucose utilization (Trends Endocrinol. Metab., 3:117 (1992)). [0008] Prolactin is a known hormone produced by the pituitary gland in all mammals. The normal biological function and activity of prolactin in mammals include regulation of reproduction, osmoregulation, the stimulation of milk production by the mammary gland, the modulation of steroidogenesis in the gonads, the stimulation of maternal behavior, and the modulation of immune function (Life Sci., 57:1 (1995)). [0009] The human placenta expresses two proteins with significant structural homology to human growth hormone, namely human placental lactogen and a variant of human growth hormone, hGH-V, differing by 13 amino acid substitutions (Hormonal Proteins Peptides, 4:61 (1977)). [0010] Human placental lactogen is somatotropic in fetal tissues and aids in stimulating mammary cell proliferation (Endocrin. Rev., 12:316 (1991)). Human growth hormone variant rather than pituitary growth hormone regulates maternal metabolism during the second half of the pregnancy (Endocrinology, 133:1292 (1993)). As described in Endocrinology, 121:2055 (1987) rodent placentas express and secrete several proteins such as proliferin and proliferin-related peptide possessing biological actions similar to prolactin rather than growth hormone. [0011] The human placenta serves as the major respiratory, nutritional and endocrine organ throughout fetal life and is critical to the survival and healthy development of the fetus. The placenta provides an intimate interface between the maternal and fetal blood supplies. Pathological impairment of placental invasion and poor vascular development has been associated with both fetal and maternal complications. [0012] Intrauterine fetal growth restriction (IUGR) is a condition that affects approximately 500,000 pregnancies annually in the United States. As a result of poor placental blood supply, and decreased fetal oxygenation and nutrition, this condition results in small-for-dates infants. These infants have a neonatal mortality rate 6-10 times higher than that of normal infants and are at risk for pulmonary and neurological problems at birth. [0013] Preeclampsia, a condition that affects approximately 250,000 American pregnancies each year, puts mothers and their fetuses at high risk. Maternal hypertension, renal failure, hepatic failure, coagulopathy, cerebral edema seizures and stroke are the potential consequences of this syndrome. Fetal morbidity is 5 times higher than normal in preeclampsia. [0014] Pathological conditions involving excessive trophoblastic invasion, such as placenta accreta and gestational trophoblastic tumors, can cause devastating maternal complications including hemorrhage and metastatic neoplasia. [0015] All the above placental conditions associated with dysregulation of the vasculature of the developing placenta can have profound maternal and chi child health consequences. [0016] Thus, there is a need for diagnosing and treating vascular abnormalities of the placenta. These needs and others are addressed by the instant invention. SUMMARY OF THE INVENTION [0017] One aspect of the invention is an anti-angiogenic peptide substantially identical to about 10 to about 150 consecutive amino acids selected from the N-terminal end of human placental lactogen, human growth hormone, growth hormone variant hGH-V, or human prolactin, wherein the peptide [0018] (i) inhibits capillary endothelial cell proliferation and organization; [0019] (ii) inhibits angiogenesis in chick chorioallantoic membrane; and [0020] (iii) binds to at least one specific receptor which does not bind an intact full length growth hormone, placental lactogen, prolactin, or growth hormone variant hGH-V. [0021] A further aspect of the invention is an isolated nucleic acid encoding the anti-angiogenic peptide of the invention. The nucleic acid may be DNA or RNA, and may comprise cDNA sequences. [0022] A further aspect of the invention is a host cell comprising the nucleic acid encoding the anti-angiogenic peptide of the invention. A further aspect of the invention is a method of producing the peptide of the invention, comprising expressing the nucleic acid in the host cell, and recovering the peptide. [0023] A further aspect of the invention is a method of treating an angiogenic disease in a subject, the method comprising administering to a subject in need of such treatment an angiogenesis inhibitory effective amount of the antiangiogenic peptide of the invention. [0024] A further aspect of the invention is a method of inhibiting tumor formation or growth in a patient, the method comprising administering to the patient an angiogenesis inhibitory effective amount of the antiangiogenic peptide of the invention. [0025] A further aspect of the invention is a method for diagnosing a probable abnormality of placental vascularization during pregnancy comprising assaying a level of at least one of endogenous N-terminal fragments of growth hormone, prolactin, growth hormone variant hGH-V, and placental lactogen in a tissue sample from a patient; and [0026] comparing the level of the at least one of endogenous N-terminal fragments to an average level of the at least one of endogenous N-terminal fragments in a normal patient population; [0027] wherein a level of the at least one of endogenous N-terminal fragments higher than the average level is a probable abnormality of placental vascularization during pregnancy. Continue reading about Novel antiangiogenic peptide agents and their therapeutic and diagnostic use... Full patent description for Novel antiangiogenic peptide agents and their therapeutic and diagnostic use Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Novel antiangiogenic peptide agents and their therapeutic and diagnostic use patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Novel antiangiogenic peptide agents and their therapeutic and diagnostic use or other areas of interest. ### Previous Patent Application: Class iii slrp for the treatment of cancer Next Patent Application: Peptide mixture from peptides having a molecular weight of from 1000 to 5000 dalton Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Novel antiangiogenic peptide agents and their therapeutic and diagnostic use patent info. IP-related news and info Results in 0.30156 seconds Other interesting Feshpatents.com categories: Electronics: Semiconductor , Audio , Illumination , Connectors , Crypto , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
